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Abstract 
Background 
Cardiac abnormalities are frequent in patients with atherosclerotic renovascular 
disease (ARVD). The ASTRAL trial studied the effect of percutaneous renal 
revascularization combined with medical therapy compared to medical therapy alone 
in 806 patients with ARVD.  
Methods 
This was a pre-specified sub-study of ASTRAL, designed to consider the effect of 
percutaneous renal artery angioplasty and stenting on change in cardiac structure and 
function, measured using cardiac magnetic resonance (CMR) imaging. 
Fifty-one patients were recruited from 6 selected ASTRAL centers. Fourty-four 
completed the study (medical therapy n=21; revascularization n=23). Full analysis of 
CMR was possible in 40 patients (18 medical therapy and 22 revascularization).   
CMR measurements of left and right ventricular end systolic (LV and RVESV) and 
diastolic volume (LV and RVEDV), ejection fraction (LVEF) and mass (LVM) were 
made shortly after recruitment, and before revascularization in the interventional 
group, and again after 12-months.  Reporting was performed by CMR analysts 
blinded to randomization arm. 
Results 
Groups were well matched for mean age (70 vs. 72 years), blood pressure (148/71 vs. 
143/74 mmHg), degree of renal artery stenosis (75 vs. 75%) and co-morbid 
conditions.  
In both randomized groups, improvements in cardiac structural parameters were seen 
at 12-months, but there were no significant differences between treatment groups.  
Median left ventricular changes between baseline and 12 months (medical vs. 
revascularization) were LVEDV -1.9 vs. -5.8 ml, p=0.4; LVESV -2.1 vs. 0.3 ml, 
p=0.7; LVM -5.4 vs. -6.3 g, p=0.8 and LVEF -1.5 vs. -0.8%, p=0.7. Multivariate 
regression also found that randomized treatment assignment was not associated with 
degree of change in any of the CMR measurements.   
Conclusions 
In this sub-study of the ASTRAL trial, renal revascularization did not offer additional 
benefit to cardiac structure or function in unselected patients with ARVD.   
 
Clinical trials registration 
Current controlled trials number: ISRCTN59586944. 
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Introduction 
Patients with atherosclerotic renovascular disease (ARVD) have a high prevalence of 
cardiac structural and functional abnormalities(1) and they are at high risk of 
cardiovascular mortality. A cross-sectional echocardiographic study of 79 ARVD 
patients showed that only 5% had structurally normal hearts, and that although left 
ventricular ejection fraction (LVEF) (mean 53%) was surprisingly well preserved, left 
ventricular hypertrophy (LVH) was present in 79% and evidence of diastolic 
dysfunction in 75%(2).  This burden of structural abnormalities in patients with 
ARVD is higher than is seen in chronic kidney disease (CKD)(3,4) or 
hypertension(5).  
 
There is evidence that increase in left ventricular mass (LVM) predisposes to 
development of chronic heart failure (CHF) in CKD of any cause(6). Heart failure, 
either flash pulmonary edema (FPE) or CHF, is a well-recognized clinical 
presentation for ARVD. Although the hearts of patients with FPE have not been 
subject to systematic study, Kane et al did examine the hearts of ARVD patients being 
referred for renal revascularization at the Mayo clinic(7), dividing patients into those 
with and without clinical heart failure; mean LVM was greater in those with CHF 
(LVM index 130±34 vs. 112±31 g/m2).  Randomized controlled trials comparing the 
addition of percutaneous renal artery revascularization to optimal medical therapy in 
ARVD have, at best, shown only minor and inconsistent benefits in blood pressure 
control(8-10).  However, case-reports have described both reductions in circulating 
levels of angiotensin II following non-randomized intervention(11), and 
improvements in left ventricular structural and functional parameters(11,12).   
 
The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial commenced 
recruitment in 2002(9). The aim of this randomized controlled trial (RCT) in 806 
patients with anatomically significant atherosclerotic RAS was to determine if renal 
revascularization provided additional clinical benefit to medical therapy. The primary 
outcome measure was renal functional improvement measured using serum 
creatinine, with secondary outcomes including blood pressure control, renal events, 
cardiovascular events and death. At the time of initiating recruitment into ASTRAL, 
there were no RCTs that had examined the effect of renal revascularization upon the 
hearts of patients with ARVD. This cardiac magnetic resonance (CMR) sub-study of 
ASTRAL was therefore developed, with the aim of examining the effects of 
revascularization upon cardiac structure and function within the setting of an RCT.  
 
Methods 
Study design 
Full details of the design of ASTRAL have been published previously(9).  In brief, 
this was a multicenter, non-blinded randomized clinical trial comparing rate of change 
in renal function between patients managed with percutaneous renal artery 
revascularization in addition to medical therapy against those managed with medical 
therapy alone.  Support was received from the Medical Research Council UK, Kidney 
Research UK, and Medtronic.  Ethical approval was granted by the West Midlands 
Multicentre Research Ethics Committee and the ethics committee relevant to each 
individual participating study center.  All patients provided written consent. Ethical 
permission for the cardiac sub-studies was obtained after commencement of the main 
ASTRAL trial. 
 
Patient selection and randomization 
Patients were eligible for inclusion within the main ASTRAL study if they had at 
least one renal artery with an atherosclerotic stenosis suitable for percutaneous 
revascularization. Patients were not enrolled if the physician was certain that the 
patient definitely should or should not undergo renal revascularization.  Patients with 
non-atheromatous disease, those who had undergone a previous revascularization 
procedure, required surgical revascularization or were considered to have a high 
probability of requiring revascularization within the next six-months on clinical 
grounds, were also excluded.  Eligible patients were randomized in a 1:1 ratio to 
revascularization in addition to standard medical therapy versus medical therapy 
alone.  Randomization was performed using a computerized minimized-
randomization procedure with allocation determined following a telephone call to the 
central trial office.   
 
For this study, all patients due to be randomized between January 2005 and October 
2007 at the six United Kingdom recruiting centers with cardiac magnetic resonance 
imaging (CMR) capacity that were participating in the sub-study were approached for 
consent.  No further inclusion criteria were applied.  The only additional exclusion 
criterion was the presence of a contra-indication to magnetic resonance imaging (e.g. 
claustrophobia, implanted metal).   
 
Sample size 
At the time of design of this sub-study there were no published data that described 
change in CMR parameters following revascularization for RAS.. One published 
study of 20 patients with ischemic CHF suggested that 15 patients per arm would be 
required to reliably detect a 3% change in left ventricular ejection fraction (LVEF); 12 
patients to detect a 10 ml difference in left ventricular end-diastolic volume 
(LVEDV); and 9 patients to detect a 10 g/m change in left ventricular mass index 
(LVMI)(13).  The sample size was therefore set at 25 patients in each treatment arm.  
Allowing for 15% dropout the total recruitment target was 58 patients.   
 
Treatment and follow-up 
Medical therapy and renal revascularization procedures were performed in accordance 
with local guidelines for each participating center as described previously.  As in the 
main ASTRAL study protocol, patients in the CMR sub-study underwent a repeat 
assessment at 12-months which included repeat of baseline clinical measurements, 
creatinine, haemoglobin and review of prescribed medications. Estimated glomerular 
filtration rate (eGFR) was calculated using the Cockcroft-Gault formula(14) as the 
study pre-dated widespread application of the MDRD formula.  Blood pressure 
measurements were performed by trained staff using mercury sphygmomanometers 
after patients had been seated at rest for five minutes, with the elbow supported above 
the waist and the palm facing upwards. Three readings were taken, with the average 
of the second and third values recorded.  
 
Cardiac magnetic resonance imaging protocol and analysis 
A single unified CMR protocol was agreed between participating centers with 
imaging performed at baseline and 12-months following randomization.  Imaging was 
performed with a 1.5-Tesla scanner using a phased array chest coil and gated with 
prospective or retrospective electrocardiographic triggering using fast imaging with 
steady-state precession. Transverse scout images were used to obtain left ventricular 
vertical long-axis cine by aligning the LV apex with the center of the mitral valve at 
end expiration.  From the ventricular long-axis image, a short axis view was obtained 
parallel to the mitral valve halfway between mitral annulus and LV apex at end 
expiration. From the short axis view the horizontal long-axis 4 chamber plane was 
aligned passing just above the inferior papillary muscle and through the lower anterior 
RV free wall where it meets the inferior wall.  This was obtained as a cine image at 
end expiration. A diastolic image at end-expiration provided the reference image on 
which a stack of contiguous short-axis slices were positioned. Breath-hold short-axis 
cine sections were acquired from the atrio-ventricular ring to the apex, with 6.0-mm 
section thickness and a 4.0-mm gap and one or 2 sections per breath hold depending 
on patient abilities and scanner speed. 
 
All scans were read by a single observer, who was an experienced CMR analyst, 
blinded to the date and order of the scan, as well as to all clinical information 
including randomization arm. End-systole was defined visually as the phase with the 
smallest LV volumes. In selection of the most basal slice for left ventricular analysis, 
slices were considered to be within the left ventricle if the blood volume was 
surrounded by 50% or more of ventricular myocardium. The apex was the most apical 
slice in which myocardium remains visible for analysis. On each end-diastolic frame, 
endocardial and epicardial borders were manually traced, and an endocardial border 
was traced on the end systolic frame. Papillary muscles and trabeculations were 
included with the LV mass while right ventricular trabeculations arising from the 
interventricular septum were excluded. Right ventricular volumes were obtained from 
true trans-axial cine sections. From these values end-diastolic and end-systolic 
volumes were calculated as well as left ventricular myocardial mass determined by 
multiplying myocardial tissue volume by the specific gravity of 1.05.  
 
Outcome measures 
Cardiac structure and function was assessed using a variety of measures including left 
ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume 
(LVESV), left ventricular ejection fraction (LVEF) and left ventricular mass (LVM) 
(and similarly for the right side).   
 
Statistical analysis 
Analyses were performed on an intention to treat basis with patients analysed in the 
treatment group to which they were randomized.  For all CMR parameters both mean 
± standard deviation and median [interquartile range] were calculated at baseline and 
12-months.  Mean differences between treatment groups were compared using 
Student’s t-test with results presented as mean difference (95% confidence interval); 
median differences were compared using Wilcoxon 2-sample test. Multivariate 
regression models were constructed to consider the effects of clinically relevant 
baseline variables (treatment group, age, presence of diabetes, history of coronary 
heart disease, systolic blood pressure, diastolic blood pressure, degree of stenosis to 
most affected kidney, renal function, prescription of beta-blockers and renin 
angiotensin blockade, baseline ventricular measurement) on change in ventricular 
parameters at 12-months.  All analyses were performed using SAS version 9.1 (SAS 
Institute, Cary, NC, USA).   
 
Results 
Patients and clinical characteristics 
A total of 806 patients were recruited to the main ASTRAL study.  Between January 
2005 and October 2007, 51 patients were enrolled into the CMR sub-study at the 6 
participating sites.  Seven patients dropped out due to death (n=1) or failure to 
complete 12-month CMR (n=6), giving a final study population of 44 (21 randomized 
to medical therapy, 23 to medical therapy plus revascularization. Three of the patients 
randomized to revascularization failed to undergo the stent insertion procedure; no 
patient in the medical therapy arm received revascularization. CMR quality was 
adequate for full analysis in 18 medical therapy and 22 revascularized patients. 
 
Baseline patient characteristics and co-morbidities were well matched between 
treatment groups and were representative of the main study population (Table 1).  All 
patients had a RAS of >50% on pre-randomization angiography (MR, CT or direct 
angiography) with mean RAS estimated at 75% in the most severely affected artery in 
each group.  Mean serum creatinine in the medical group was 160 (range 74-242) 
μmol/L, compared with 146 (79-201) μmol/L in the revascularization group; no 
patients had a baseline creatinine in excess of 300 μmol/L.  Height data were only 
available for a minority of patients, and consequently LVM data were considered 
without adjustment for patient height.  In line with the findings of the main study, no 
significant difference in change in blood pressure or renal function existed between 
randomized treatment groups at 12-months.  
 
Cardiac MR imaging : left ventricular parameters  
At recruitment, all left ventricular structural parameters were similar between the 
medical and revascularization treatment groups with LVEDV median 130ml [IQR: 
108 to 146] vs. 122ml [97 to 146]; LVESV 40ml [33 to 51] vs. 38 ml  [29 to 60]; 
LVM 116g [98 to 134] vs. 110g  [101 to 132] (Table 2). Non-significant 
improvements in these structural parameters were observed within both randomized 
arms between baseline and 12 months with median changes for medical and 
revascularization groups, respectively, being LVEDV -1.9ml [95% CI -21 to 4] and -
5.8ml [95% CI -17 to 6]; LVESV -2.1ml [95% CI -5 to 4] and 0.3ml [95% CI -11 to 
5]; LVM -5.4g [95% CI -12 to 6].and -6.3g [95% CI -15 to -0.2].  Comparisons 
between randomized groups were made for measured left ventricular values at 12-
months and for the relative difference between the two arms for the change from 
baseline to 12-month values.  In both analyses, no significant difference between 
randomized treatment groups was observed (Table 2).  
At baseline, left ventricular ejection fraction was well preserved in both groups, 
medical therapy 69.5% [63 to 73], revascularization 69.2% [59 to 72] (Table 2). 
Within each treatment group, minimal differences in ejection fraction were observed 
at 12-months.  There was no significant difference in the between group comparison 
of measured 12-month ejection fraction (Table 2) and relative change from baseline 
ejection fraction (Table 3).  
 
Cardiac MR imaging : differences in right ventricular parameters 
Although this sub-study was designed to assess differences in left sided parameters, 
right heart measurements were also obtained (Table 2).  No difference in right 
ventricular EDV, ESV or ejection fraction was observed between groups either at 
baseline or at 12-months.   
 
Association between baseline variables and change in left ventricular parameters at 
12-months 
Sufficiently complete data were available for 31 patients (15 medical therapy, 16 
revascularized) to be included in multivariate regression models.  Each model was 
constructed twice using either serum creatinine or eGFR as one of the co-variates in 
the model.  No difference in results or overall model fit (defined using adjusted R2) 
was observed so only results for models using eGFR are presented. Treatment 
allocation was not significantly associated with any left ventricular parameter 
(LVEDV, LVESV, LVM, or LVEF) at 12-months. However, a significant association 
between use of renin angiotensin blockade (RAB; angiotensin converting enzyme 
inhibitor or angiotensin receptor blocker) and certain ventricular measurements at 12-
months was observed: LVEDV (parameter estimate 17.4 [standard error 7.4] p=0.03), 
LVESV (10.6 [4.1] p=0.02) and LVEF (-4.48 [2.1] p=0.04).  LVEDV at 12 months 
was also associated with baseline diastolic blood pressure (0.90 [0.4] p=0.04).  
 
Complications of revascularization 
Procedural complications were not separately analyzed for this sub-study.  In the main 
ASTRAL study, serious complications were observed in 23 of 403 patients 
randomized to revascularization.  This included 2 deaths occurring within 30-days of 
intervention.   
 
Discussion 
This study has not identified any definitive evidence or even signals of additional 
benefit of renal artery revascularization on left or right ventricular structure or 
function in patients with atherosclerotic RAS and significant renal impairment.   
 This finding is in alignment with results of the Renal Artery Stenosis in Coronary 
Artery Disease (RASCAD) study(15), a randomized trial of 84 patients with 
atherosclerotic RAS identified on screening during non-emergency coronary 
angiography, and in which the effect of revascularization in addition to medical 
therapy was considered in relation to change in left ventricular mass index over a 12-
month period.  Although patient age was similar other demographics differed from 
those described in this ASTRAL sub-study, with patients recruited to RASCAD 
having a lesser degree of RAS (60%), lower systolic blood pressure (around 132 
mmHg) and higher baseline eGFR (approximately 60 ml/min). Nevertheless, 
RASCAD also found that no additional reduction in LVMI was seen in revascularized 
patients in comparison with medically managed patients, and that LVMI did decrease 
in both randomised groups. As these two small randomized trials have not confirmed 
the findings of case series(12) that suggest a significant association between renal 
artery revascularization and improved left ventricular structure  the potential of a false 
negative should be considered. In a 12-month echocardiographic series of 43 patients 
with varying degrees of RAS, LVM remained stable over the follow-up period(16).  
Only 8 of these patients underwent revascularization and there was a signal towards 
reduced LVMI and LVEDV index in this sub-group. However, these measurements 
were made using transthoracic echocardiography, which is much less accurate than 
CMR(17). As this study failed to recruit sufficient patients to satisfy the power 
calucation, it is possible that a genuine effect was missed.  However, if this was the 
case, then the difference would be small and of limited clinical relevance.  
 
The improvements in structural left ventricular measurements at 12-months seen in 
both of the randomized arms in this study may reflect appropriate use of 
pharmacotherapy.  Since the first trials of percutaneous revascularization for RAS, the 
nature of what constitutes optimal medical therapy in renovascular disease has been 
better defined.  Most notably there has been a better appreciation of the importance of 
use of RAB and statin therapy(18-20). RAB has a role in both preventing progression 
and inducing regression of left ventricular mass, independent of changes in blood 
pressure, in other populations(21,22). Although the effect of medication may have 
marginalized any potential benefits of revascularization in our study, it was surprising 
that we found use of RAB at baseline was associated with slight deterioration of 
LVEDV, LVESV and LVEF at 1 year.   
 
A further question that merits discussion is whether more subtle measures of cardiac 
structural health should be considered. Contemporary CMR techniques permit 
assessment of myocardial edema and or fibrosis allowing in depth interrogation of 
myocardial pathology, potentially identifying patients at higher risk of cardiac 
events(23).  Angiotensin II mediated hypertension has been shown to drive 
myocardial fibrosis(24,25); it may be that in our ARVD patients chronic 
overstimulation of the renin-aldosterone-angiotensin system had led to irreversible 
cardiac structural changes by the time of diagnosis.  A developing body of literature 
suggests that a higher burden of myocardial edema (a precursor to development of 
fibrosis(26)) is associated with an increased likelihood of left ventricular 
remodeling(27,28), and so, theoretically, identification of patients with greater 
degrees of myocardial edema may select a group with greater likelihood of benefiting 
from revascularization. Given the systemic atheromatous burden associated with 
ARVD, development of cardiac abnormalities will be a multifactorial process driven 
by pre-existing essential hypertension and/ or coronary artery disease as well as RAS. 
Some of these processes will be unaffected by revascularization. Hence, perhaps only 
those left ventricular abnormalities that are still progressing and are primarily related 
to RAS should be expected to improve after revascularization. Speckle track 
echocardiography can demonstrate more subtle abnormalities in myocardial function, 
manifest by changes in LV strain patterns, and this is being increasingly investigated 
in patients with CKD(29). Although CMR protocols with tagging can replicate this, 
we only evaluated conventional cardiac parameters in this study. 
 
This study has limitations.  Most importantly, the sample size was small and the 
sample size calculation may have been flawed because it was based on CMR data 
from a small number of patients with CHF, as little other data was available at the 
time of designing the study.  However, given the similarity in outcome between 
randomized groups it seems unlikely that a larger sample size would have altered the 
overall findings in this patient group.  It is noteworthy that this was a sub-study of a 
much larger ARVD population in which no overall benefit from renal artery 
revascularization was observed. As such it is perhaps unsurprising that no difference 
in change in cardiac structure of function was identified between groups.  The issue of 
patient selection is also important to consider.  The suggested bias towards 
recruitment of lower risk patients (less likely to benefit from revascularization) into 
ASTRAL has been widely discussed(30).  In those case series that have described 
cardiac benefits from revascularization, patients have either had a greater burden of 
stenosis(12), or more severe symptoms of heart failure at baseline(11), than that seen 
in the ASTRAL population.  It is plausible that a study targeting more specific cardiac 
risk patient groups (e.g. ARVD patients with NYHA III-IV symptoms, or those with 
very severe hypertension) might demonstrate beneficial cardiac changes 
accompanying renovascular intervention. 
  
In conclusion, in this study the addition of renal artery revascularization to standard 
medical therapy did not lead to any further changes in cardiac structure or function 
than management with medical therapy alone.  This finding was in a patient cohort in 
whom no benefit from revascularization was observed in relation to rate of change in 
renal function, cardiovascular events, or death.  Current guidelines recognize that 
some patients may be more likely to benefit from revascularization, for example 
patients with acute or chronic heart failure or with resistant hypertension(31) with 
supporting evident for this in large case series(32).  These may be patient groups in 
whom improvements in cardiac structure are more likely to follow revascularization.  
This sub-study was inadequately powered to consider effects in specific sub-groups, 
and patients with acute heart failure were not included in ASTRAL.  Future studies 
that investigate whether cardiac structural and functional changes might accompany 
renal artery revascularization should address carefully selected patient populations.   
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 Table 1 – Baseline patient characteristics 
 
 Medical 
Management (N = 
21) 
Revascularisation 
(N = 23) 
P value 
Demographic 
Mean age (range) – years  70  (51 - 81) 72  (53 - 85) 0.47 
Male sex – % 71% 65% 0.66 
    
Mean weight (range) – kg 79  (60 – 105) 75  (60 – 95) 0.3 
Clinical 
Smoking status – %    
Current smoker 26% 28% 0.92 
Former smoker 58% 56% 0.89 
    
Coexisting conditions – %    
Diabetes 40% 32% 0.58 
Coronary heart disease 56% 68% 0.43 
Peripheral vascular disease 47% 28% 0.25 
Stroke 42% 26% 0.31 
Need for dialysis 0 0 - 
Renal Function 
Serum Creatinine    
Mean (range) – μmol/litre 160  (74 - 242) 146  (79 - 201) 0.24 
        Level – %    
< 150 μmol/litre 38% 52% 0.35 
150-300 μmol/litre 62% 48%  
> 300 μmol/litre 0 0  
Rapid Increase in SCr * 6% 6% 0.97 
    
Estimated glomerular filtration rate    
Mean (range) – ml/min 42.4  (18.1 – 72.9) 43.0  (17.0 – 89.8) 0.89 
        Level – %    
< 25 ml/min 10% 9% 0.45 
25-50 ml/min 57% 74%  
> 50 ml/min 33% 17%  
    
    
    
Related Laboratory Measures¶ 
Mean blood pressure (range) – mmHg    
Systolic 148  (90 - 220) 143  (113 - 186) 0.58 
Diastolic  71  (57 - 94) 74  (52 - 102) 0.53 
    
Mean total cholesterol (range) – 
mmol/litre 
4.5  (2.8 – 7.7) 4.8  (3.2 – 14.8) 0.75 
Renal anatomy 
Stenosis    
Mean (range) – % 75.2  (50 - 90) 75.4  (60 - 90) 0.96 
        Severity – %    
< 50% 0 0 0.38 
50-70% 52% 39%  
> 70% 48% 61%  
Mean length of kidney (range) – cm  9.7  (7.5 – 11.5) 9.5  (7.7 – 11.2) 0.77 
Use of Concomitant medication 
Antihypertensive drug –  %    
Any 100% 89% 0.15 
Diuretic 58% 76% 0.24 
Calcium-channel blocker 79% 41% 0.02 
Beta-blocker 47% 53% 0.74 
Angiotensin blockade 53% 65% 0.46 
Alpha-blocker 37% 29% 0.64 
Mean no. of antihypertensive drugs 
(range) 
2.8  (2 - 5) 2.8  (1 – 5) 0.92 
    
Antiplatelet drug – no./total no. (%)    
Any  90% 95% 0.58 
Aspirin 89% 83% 0.64 
    
Cholesterol lowering drug – no./total no. 
(%) 
   
Any 94% 95% 0.97 
Statin 100% 94% 0.32 
    
Warfarin – no./total no. (%) 16% 11% 0.68 
    
Angiotensin blockade defined as prescription of angiotensin converting 
enzyme inhibitor or angiotensin-receptor blocker 
*Rapid increase in serum creatinine defined as an increase of greater than 
100μmol/l or greater than 20% from baseline reading during the previous 1-
year prior to randomisation 
Table 2: Cardiac MRI data at baseline and 1 year  
 
 
Baseline 1 Year  
Medical 
Management  
(n=21) 
Revasc  
(n=23) 
Medical 
Management  
(n=18) 
Revasc  
(n=22) 
p between 
groups at 1 year 
 
LVD volume (ml) Mean (SD) 130.3  (26.0) 133.2  (46.6) 121.2  (35.2) 132.9  (48.3) 0.4 
Median (IQR) 129.7 
(108.0, 145.9) 
122.4 
(96.6, 145.5) 
124.7 
(106.1, 146.1) 
118.5 
(104.6, 114.5) 
1.0 
LVS volume (ml) Mean (SD) 44.6  (18.6) 53.4  (46.6) 44.0  (22.9) 54.2  (45.8) 0.4 
Median (IQR) 39.8 
(32.6, 50.6) 
37.6 
(28.7, 59.6) 
40.8 
(26.2, 55.8) 
40.3 
(26.9, 50.3) 
1.0 
LV mass (g) Mean (SD) 116.4  (28.6) 111.4  (21.1) 108.5  (30.6) 104.3  (20.1) 0.6 
Median (IQR) 116.1 
(97.8, 134.4) 
110.1 
(100.9, 132.3) 
106.8 
(98.1, 128.1) 
103.8 
(88.9, 111.9) 
0.5 
Adjusted LV mass (g/m2) * Mean (SD) 62.2  (21.8) 64.9  (14.2) 57.9  (20.5) 59.0  (13.4) 0.9 
Median (IQR) 64.1 
(41.9, 81.4) 
62.2 
(55.2, 79.9) 
60.8 
(40.4, 73.1) 
60.1 
(54.5, 67.3) 
1.0 
LV ejection fraction (%) Mean (SD) 66.3  (10.3) 63.8  (15.3) 64.7  (13.1) 63.3  (14.1) 0.7 
Median (IQR) 69.5 
(62.9, 72.6) 
69.2 
(59.1, 72.3) 
65.0 
(56.1, 74.2) 
66.0 
(58.1, 72.1) 
0.8 
RVD volume (ml) Mean (SD) 122.7  (30.1) 112.3  (22.7) 118.3  (32.5) 113.4  (21.9) 0.6 
Median (IQR) 115.2 
(100.4, 145.6) 
113.9 
(93.4, 129.9) 
111.5 
(89.8, 141.9) 
117.4 
(98.4, 126.4) 
0.7 
RVS volume (ml) Mean (SD) 45.9  (16.6) 39.3  (8.7) 45.3  (16.7) 40.8  (10.4) 0.3 
Median (IQR) 42.4 
(36.5, 54.8) 
39.0 
(32.3, 44.3) 
43.9 
(29.8, 62.6) 
39.1 
(33.5, 49.6) 
0.5 
RV mass (g) Mean (SD) 34.4  (9.4) 34.8  (7.0) 34.3  (10.2) 35.4  (10.5) 0.7 
Median (IQR) 30.9 
(27.1, 40.0) 
34.5 
(29.3, 40.1) 
32.9 
(29.8, 41.2) 
32.1 
(28.5, 40.8) 
0.7 
Adjusted RV mass (g/m2) * Mean (SD) 18.4  (3.8) 19.4  (1.9) 19.2  (6.1) 21.7  (8.1) 0.5 
Median (IQR) 19.0 
(15.4, 22.5) 
19.5 
(18.7, 20.8) 
21.4 
(14.3, 23.6) 
20.0 
(17.8, 24.6) 
0.9 
RV ejection fraction (%) Mean (SD) 62.8  (8.9) 64.8  (5.3) 61.8  (9.5) 63.9  (6.8) 0.4 
Median (IQR) 65.1 
(56.8, 67.8) 
65.6 
(61.8, 68.8) 
63.1 
(54.3, 67.3) 
65.1 
(57.4, 70.2) 
0.4 
 
 
* For body surface area adjusted measurements, data available for 13 patients are baseline (7 medication, 6 PTRAS) and 17 patients at 12 months (8 medical, 9 PTRAS).
Table 3: Change in cardiac structural measurements between baseline and 1 year in medical management and PTRAS groups 
 
 
Medical 
Management 
Revasc p 
LVD volume (ml)  Mean (SD) -8.2  (18.7) -0.8  (17.8) 0.2 
Median (IQR) -1.9 
(-21.5, 4.3) 
-5.8 
(-17.0, 5.9) 
0.4 
LVS volume (ml) Mean (SD) -1.4  (10.0) -0.7  (11.5) 0.8 
Median (IQR) -2.1 
(-4.8, 3.8) 
0.3 
(-11.3, 5.0) 
0.7 
LV mass (g) Mean (SD) -4.0  (14.0) -6.9  (14.8) 0.5 
Median (IQR) -5.4 
(-11.9, 5.6) 
-6.3 
(-15.2, -0.2) 
0.8 
Adjusted LV mass (g/m2)  Mean (SD) -5.0  (7.2) 0.9  (8.9) 0.2 
Median (IQR) -7.7 
(-9.4, 3.3) 
0.6 
(-3.8, 7.6) 
0.3 
LV ejection fraction (%) Mean (SD) -0.9  (6.2) 0.4  (5.0) 0.5 
Median (IQR) -1.5 
(-3.2, 3.8) 
-0.8 
(-3.0, 3.4) 
0.7 
RVD volume (ml) Mean (SD) -3.6  (20.7) 1.9  (16.3) 0.3 
Median (IQR) 0.2 
(-10.2, 7.8) 
1.7 
(-5.9, 6.1) 
0.7 
RVS volume (ml) Mean (SD) -0.3  (13.0) 1.4  (9.1) 0.6 
Median (IQR) 2.1 
(-6.9, 10.0) 
-0.9 
(-3.6, 4.2) 
0.8 
RV mass (g) Mean (SD) -0.3  (7.8) 0.8  (11.8) 0.7 
Median (IQR) 0.2 
(-3.1, 5.8) 
-2.5 
(-6.8, 2.4) 
0.6 
Adjusted RV mass (g/m2)  Mean (SD) 0.3  (5.0) 1.1  (5.2) 0.8 
Median (IQR) -1.1 
(-2.1, 6.1) 
0.4 
(-1.2, 6.0) 
0.8 
RV ejection fraction (%) Mean (SD) -0.9  (4.9) -0.6  (5.8) 0.9 
Median (IQR) -1.5 
(-4.0, 0.8) 
1.2 
(-4.2, 3.8) 
0.6 
 
 
